{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"254"}]}],"title":"Patient 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"330"}]}],"title":"Patient 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"985"}]}],"title":"Patient 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Duration of response (DOR) is defined as time from the first documented response to the date first documented disease progression or relapse or death due to any cause. For patients with solid tumors the assessment criteria will be RECIST 1.1 and will include responses of CR and/or PR.","groups":[{"description":"LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.","id":"OG000","title":"Ribociclib 600 mg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 36 months","title":"Number of Days for Duration of Response for Responders","type":"SECONDARY","unitOfMeasure":"Days"}